



Interleukin-2-Inducible T-Cell Kinase Deficiency—New Patients, New Insight?

Sujal Ghosh^{1*}, Ingo Drexler², Sanil Bhatia¹, Heiko Adler^{3,4,5}, Andrew R. Gennery⁶ and Arndt Borkhardt¹

¹ Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-University, Düsseldorf, Germany, ² Institute for Virology, Medical Faculty, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany, ³ Research Unit Lung Repair and Regeneration, Comprehensive Pneumology Center, Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Munich, Germany, ⁴ University Hospital Grosshadern, Ludwig-Maximilians-Universität München, Munich, Germany, ⁵ German Center for Lung Research (DZL), Giessen, Germany, ⁶ Paediatric Immunology and HSCT, Newcastle University and Great North Children's Hospital, Newcastle upon Tyne, United Kingdom

OPEN ACCESS

Edited by:

Isabelle Meyts,
KU Leuven, Belgium

Reviewed by:

Stuart G. Tangye,
Garvan Institute of Medical
Research, Australia
Shigeaki Nonoyama,
National Defense Medical
College, Japan
Pamela Lee Schwartzberg,
National Institutes of Health
(NIH), United States

*Correspondence:

Sujal Ghosh
sujal.ghosh@med.
uni-duesseldorf.de

Specialty section:

This article was submitted to
Primary Immunodeficiencies,
a section of the journal
Frontiers in Immunology

Received: 23 October 2017

Accepted: 20 April 2018

Published: 08 May 2018

Citation:

Ghosh S, Drexler I, Bhatia S, Adler H,
Gennery AR and Borkhardt A
(2018) Interleukin-2-Inducible
T-Cell Kinase Deficiency—
New Patients, New Insight?
Front. Immunol. 9:979.
doi: 10.3389/fimmu.2018.00979

Patients with primary immunodeficiency can be prone to severe Epstein-Barr virus (EBV) associated immune dysregulation. Individuals with mutations in the interleukin-2-inducible T-cell kinase (*ITK*) gene experience Hodgkin and non-Hodgkin lymphoma, EBV lymphoproliferative disease, hemophagocytic lymphohistiocytosis, and dysgammaglobulinemia. In this review, we give an update on further reported patients. We believe that current clinical data advocate early definitive treatment by hematopoietic stem cell transplantation, as transplant outcome in primary immunodeficiency disorders in general has gradually improved in recent years. Furthermore, we summarize experimental data in the murine model to provide further insight of pathophysiology in *ITK* deficiency.

Keywords: primary immunodeficiency, combined immunodeficiency, interleukin-2-inducible T-cell kinase, Epstein-Barr virus-related malignancies, lymphoproliferative disorders

INTRODUCTION

Epstein-Barr virus (EBV) is recognized to cause infectious mononucleosis. More than 90% of the global population carries the latent virus life-long and most individuals acquire the gammaherpesvirus by silent infection at young age. Several malignancies are associated with EBV and in the last decades patients with genetic defects of T cell signaling or cytotoxic pathway have demonstrated susceptibility to severe immune dysregulation upon EBV infection or reactivation. They usually present with fatal infectious mononucleosis, lymphoma and lymphoproliferative disease (LPD), hemophagocytic lymphohistiocytosis (HLH), and dysgammaglobulinemia (1, 2).

While many combined immunodeficiencies (e.g., defects of antigen receptor recombination *RAG1/2*) can lead to EBV immune dysregulation beside other infectious complications, there are diseases, which confer a higher propensity only of EBV associated disease. Several genes have been linked to EBV lymphoproliferation (*SH2D1A*, *STK4*, *CD27*, *CD70*, *LAT*, *RASGRP1*, *MAGT1*, *Coronin-1A*, and *CTPS1*) in recent years (2). Our group and others reported alterations in the interleukin-2-inducible T-cell kinase (*ITK*) gene in patients presenting with severe EBV associated dysregulation (3, 4). At least one decade earlier, murine studies had already shown that *ITK* is essential for various T cell functions, especially during a Th2 response. In this mini review, we update on clinical and immunological aspects in reported individuals and highlight the extensively investigated murine *itk*^{−/−} model.

ITK DEFICIENCY—CLINICAL PRESENTATION AND DIAGNOSIS

The first patients were reported in 2009 by our group. Two sisters from consanguineous Turkish parents presented with EBV-driven lymphoproliferative disease (3). At age of 6 years, one developed pneumocystis pneumonia, severe candida stomatitis, cytopenia, progressive hypogammaglobulinemia, and oligoclonal polymorphic B cell lymphoproliferation.

Eighteen months later, she presented with Hodgkin lymphoma (HL), which was successfully treated with chemotherapy. However, T lymphocytes were further declining and at age of 10 years the girl succumbed to pneumocystis pneumonia. The younger sister presented with pancytopenia and severely impaired hepatic function due to EBV-associated HL. Due to rapid clinical deterioration haploidentical peripheral blood stem cell transplantation (SCT) was performed as a salvage therapy, but unfortunately the patient died due to airway obstruction during aplasia. Genome-wide linkage analysis identified *ITK*, in which the causative homozygous R335W mutation was revealed. To date, we are aware of *ITK* mutations in 17 patients originating from Greece, India, Italy, Iran, Morocco, Pakistan, Palestine, and Turkey (16 patients described in **Table 1**) (5–12). These patients manifested between 2.5 months and 13 years of age and presented with fever, hepatosplenomegaly, lymphadenopathy, and EBV viremia. One patient was diagnosed at birth due to family history of disease in the older brother. Thirteen patients presented either with HL or with EBV-driven B cell lymphoproliferative disease (in some cases developing to Hodgkin or large B cell lymphoma), only two showed a classical non-HL histology. In a few patients, other viral infections including CMV and VZV were seen. Given the severe immune dysregulation, at least three patients developed autoimmune phenomena and two patients developed HLH.

The number of *ITK* patients is too few to deduce valid statistics. However, it appears that HLH occurs less frequent in *ITK* deficiency than, e.g., in SLAM-associated protein (SAP) deficiency (30%) (13).

As known from other disorders with EBV predisposition, pulmonary interstitial nodules were seen in most patients. Furthermore, progressive hypogammaglobulinemia and loss of CD4+ T cells was detected, in particular naive CD45RA+ CD4+ T cells were decreased. In parallel with other EBV prone disorders (e.g., SAP deficiency), peripheral NKT cells [determined as CD3+, T cell receptor (TCR) Vβ24+, TCR Vα24+] were decreased in *ITK*-deficient patients supporting observations in transformed cell lines that NKT cells might be essential for anti EBV immunity (14). However, there is some evidence that EBV infection itself might decrease the number of NKT cells in these patients, as normal numbers of NKT cells are demonstrated in EBV-naïve patients, e.g. in patients with XIAP deficiency (15). Furthermore, there are disorders with a global lack of NKT cells, in which individuals are rather susceptible to Mycobacteria, but not to EBV infection (16).

Peak EBV viremia in *ITK*-deficient patients was quite heterogeneous in reported patients (10^4 – 10^8 copies/μg DNA). Unfortunately, we obtained incomplete information on serological phenotype at time of manifestation to predict the time

between infection and clinical exacerbation; EBV-VCA-IgM was detected in one patient only. In contrast to one of the most similar immunological disorders—SAP deficiency—there is not a single reported EBV-VCA-IgG seronegative symptomatic EBV-LPD patient highlighting the paramount importance of EBV infection and maybe specificity in the disease setting. Interestingly the spectrum of histopathological diagnosis is quite variable in reported patients. Bienemann et al analyzed seven of the 16 patients presented here. In six events, a classic mixed-cellular HL histology was shown, while the other lymphoproliferative events were rather heterogeneous (polymorphic: three events, borderline polymorphic to monomorphic blast-rich B-cell LPD: two events, HL-like B-cell proliferation: two events and large B-cell lymphoma like LPD: two events). In contrast to many immunocompromised patients (who rather demonstrate latency type III), *ITK*-deficient patients had predominantly EBV latency type II and presented often with nodal and extranodal manifestations simultaneously (6). One patient with *ITK* deficiency differs from the other patients in several points. An 18-year-old male Turkish patient suffered from recurrent progressive pulmonary infections and bronchiectasis, but no lymphoproliferative disease. He remained EBV seronegative although PCR could detect a low EBV viral load of 1,000–2,000 copies/μl (11).

MANAGEMENT AND OUTCOME

As previously demonstrated in other EBV-LPD cases, a few patients with *ITK* deficiency were treated with Rituximab with some improvement. IgG substitution has conferred only temporary benefit, especially to partially ameliorate immune dysregulation manifesting as lymphoproliferation and autoimmunity; corticosteroids were not helpful in the reported cases. Eight patients died between 1 and 15 years after diagnosis (mostly due to malignancies), seven within 2 years from diagnosis. Nine patients did not receive definitive treatment. Most had a fatal outcome. Six patients died due to lymphoproliferation, while only two patients remained in remission after chemotherapy for HL. However, eight patients underwent hematopoietic SCT. Two patients died after HSCT. While one of the initial patients died during aplasia with hemorrhagic acute airway obstruction after receiving haploidentical PBSCT, another patient succumbed to severe graft-versus-host disease. Recently, three more patients have been reported at two different centers (Newcastle, UK and Paris, France), which have been presented orally at the Annual Meeting of the European Society for Immunodeficiencies in Edinburgh, September 2017. All three patients were diagnosed with Hodgkin-like lymphoma or diffuse B cell lymphoma like lymphoproliferation and were subject to HSCT. Remarkably, the Paris patient was treated with five courses of Rituximab and two injections of Brentuximab to achieve clinical remission before haploidentical T replete HSCT. We can learn from those cases that immunotherapy with Rituximab or Brentuximab can lead to partial or even complete remission and at least bridge to definitive cure. We strongly suggest that each patient should be carefully considered for early HSCT, once the diagnosis of *ITK* deficiency has been established.

TABLE 1 | Clinical and laboratory findings in ITK-deficient patients.

Origin	Mutation	Patient 1 Turkey c.1003C>T; p.R335W	Patient 2 Turkey c.1003C>T; p.R335W	Patient 3 Palestine c.1764C>G; p.Y588X	Patient 4 Palestine c.1764C>G; p.Y588X	Patient 5 Palestine c.1764C>G; p.Y588X	Patient 6 Morocco c.86G>A; p.R29H	Patient 7 India c.1497delT; p.D500TfsX4	Patient 8 Iran c.468delT; p.L157Ffs*108	Patient 9 Turkey c.49C>T; p.Q17X	Patient 10 Italy/Greece Comp-het c.49C>T/c.922delG; p.Q17X	Patient 11 Turkey c.49C>T; p.Q17X	Patient 12 Turkey c.49C>T; p.Q17X	Patient 13 Turkey c.1003C>T; p.R335W	Patient 14 Turkey c.1003C>T; p.R335W	Patient 15 Pakistan c.626G>A; p.W209X	Patient 16 Pakistan c.626G>A; p.W209X
Sex		Female	Female	Female	Male	Male	Male	Female	Female	Male	Female	Female	Male	Male	Female	Male	Male
Age at diagnosis		5	6	4	5	3	11	6	13	18	5	6	2.5	7	3	4	Birth
Status		Died at age 10	Died at age 7 after HSCt	Died at age 6	Remission after Cx, age 12	a/w after HSCt, age 8	Died at age 26	Died after HSCt at age 8	Died at age 15	Unknown	a/w after HSCt age 5	Died at 8	Remission after Cx	a/w after HSCt age 8	Died at 3	a/w after HSCt age 4	a/w after HSCt age 1
Fever		+	+	+	+	+	+	+	+	+	n.a.	n.a.	+	+	+	+	+
Lymphadenopathy		+	+	+	+	+	+	+	+	None	+	+	+	+	+	+	+
Hepatosplenomegaly		+	+	+	None	Unknown	Unknown	None	+	None	+	+	+	+	+	+	None
Pulmonary involvement		+	None	None	+	+	+	+	+	Infections	None	+	None	+	+	+	None
Histology		B cell LPD	HL-like B cell LPD	HL	HL	HL	B cell LPD	B cell LPD, LBCL, LG	B cell LPD	None	HL	NHL	HL	LG, Burkitt	n.a.	HL-like LPD	DLBL-like LPD
Autoimmunity		None	None	None	Nephritis, thyroiditis	Thyroiditis	AIHA/ITP	None	None	None	None	None	None	None	None	None	None
HLH		None	(+)	+	None	None	None	None	None	None	After HSCt	None	None	None	?	None	None
CD4+ cells		↓	↓	Normal	↓	Normal	↓	↓	↓	↓	n.i. (after Cx)	Normal	↘	↘	Normal	↓	Normal
CD8+ cells		Normal	↓	↑	↓	Normal	Normal	Normal	Normal	Normal	n.i. (after Cx)	Normal	Normal	Normal	Normal	↓	Normal
NKT cells		n.d.	↘	n.d.	↘	n.d.	↘	↘	n.d.	↘	n.i. (after Cx)	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
Serology		VCA-G+, VCA-M-, EA-G+, EBNA-G-	VCA-G+, VCA-M-, EBNA+	VCA-G-, VCA-M-, EBNA+	VCA-G+, VCA-M-, EBNA-G-	n.d.	VCA-G+	VCA-G+	VCA-G+	VCA-G+	n.d.	VCA-G+, VCA-M-, EBNA-G-	VCA-G+, VCA-M-, EBNA-G-	VCA-G+, VCA-M-, EBNA-G+	VCA-G+, VCA-M-, EBNA-G+	n.d.	n.d.
Viral load at presentation		10 ³	10 ³	10 ⁵	10 ³	10 ⁵	+	10 ³	10 ⁷	10 ³	n.d.	10 ⁴ CMV	10 ⁴	None	n.a.	10 ⁴	10 ⁴
Peak viral load		10 ⁷	10 ⁴	Unknown	Unknown	Unknown	10 ⁶	10 ⁴	10 ⁷	10 ³	n.d.	10 ⁴	10 ⁴	n.a.	n.a.	10 ⁴	10 ⁴

AIHA, autoimmune hemolytic anemia; Cx, chemotherapy; HL, Hodgkin lymphoma; ITP, immune thrombocytopenia; LBCL, large B-cell lymphoma; LG, lymphoproliferative disease; n.d., not determined; n.q., not quantified; HLH, hemophagocytic lymphohistiocytosis; ITK, interleukin-2-inducible T-cell kinase.

↓, decreased; ↘, lower margin; ↑, increased.

INTERLEUKIN-2-INDUCIBLE T-CELL KINASE

Interleukin-2-inducible T-cell kinase is one of five mammal TEC family kinases. All five proteins are involved in lymphocyte signaling and development (17). Years before the first patient with ITK deficiency was diagnosed, *ITK-SYK* translocations were found in individuals with T cell lymphoma (18). The *ITK* gene on chromosome 5q consists of 17 exons and 112 kbp, the protein (71 kDa) is formed by 620 amino acids. ITK is composed of an N-terminal pleckstrin homology (PH), a Tec homology

(TH), an Src homology 3 (SH3), an Src homology 2 (SH2), and a C-terminal catalytic kinase domain (**Figure 1A**) (19). Upon activation of the TCR several phosphorylation events recruit ITK to the cell membrane (for details, see **Figure 1B**). ITK activates $\text{PLC}\gamma 1$, generating inositol 1,4,5-trisphosphate (IP_3), which leads to intracellular calcium release and diacylglycerol, which, *via* RASGRP and $\text{PKC}\delta$, ultimately results in activation/induction of the NF κ B, mTOR, and MAPK/ERK pathways.

Mutations were found in the kinase, SH2 and PH domain. Most patients demonstrated an autosomal-recessive trait, while in one individual a compound-heterozygous inheritance from




FIGURE 1 | Interleukin-2-inducible T-cell kinase (ITK)—structure and signaling—**(A)** domain organization of ITK and corresponding protein mutants in patients with ITK deficiency. N-terminal pleckstrin homology (PH), Tec homology, Src homology 3 (SH3), Src homology 2 (SH2), and C-terminal catalytic kinase domain. Pattern recognition receptors. In one patient, a compound heterozygous mutation is predicted to encode Q17X and A308Lfs*24 mutant. **(B)** Following engagement of the T cell receptor (TCR) with an MHC bound foreign antigen, several intracellular signals are activated. Lck is recruited and phosphorylates immunoreceptor tyrosine-based activation motifs (ITAM) at the zeta chain of the TCR. ZAP70 binds double-phosphorylated ITAM residues and phosphorylates LAT, which is recruited to the TCR complex. Phosphorylated LAT recruits SLP76, which together with Itk, activates $\text{PLC}\gamma 1$. Subsequently phosphatidylinositol 4,5-bisphosphate (PIP_2) is catalyzed into inositol 1,4,5-trisphosphate (IP_3), which leads to intracellular calcium release and diacylglycerol (DAG). DAG itself can recruit $\text{PKC}\delta$ and RASGRP, which induce the NF κ B and MAPK/ERK pathways.

two different ethnicities (Greek–Italian) was revealed (5). Interestingly there are corresponding mutations in residues of the “sister” Tec kinase *BTk* (known to cause X-linked agammaglobulinemia), which are homologous to the mutations observed in our patients (9). Our group transformed Herpesvirus saimiri cell lines to reveal functional impairment in corresponding ITK mutations.

The alterations did not greatly change the amount of *ITK* mRNA expression, nevertheless immunoblot investigations showed several variants of endogenous ITK. Most importantly, we analyzed calcium response with flow cytometric flux studies and revealed a highly decreased release of calcium ions into the cytosol in most patients. With regards to functional complementation our group restored TCR-mediated calcium flux in murine *itk*^{−/−} thymocytes by means of wild type ITK transduction.

Interestingly since the publication of our last review two new EBV prone diseases have been discovered in the proximity of ITK (with respect to location in the pathway). Linker for activation of T cells (LAT) is a transmembrane adapter molecule, which is phosphorylated after TCR triggering. It contains no intrinsic enzymatic activity and couples the TCR to downstream pathways as a scaffolding protein. PLC γ 1 phosphorylation is highly dependent on the assembly of the LAT-SLP76 signalosome. However, the two initial reports on two kindreds with LAT deficiency show different phenotypes and ambiguous results (20, 21). One kindred presented with a typical (severe) immunodeficiency phenotype with failure to thrive and recurrent infections. The other report describes a family with infants with increased autoimmunity due to combined immunodeficiency with a higher number of residual T lymphocytes. All three siblings suffered from CMV and EBV infection before autoimmunity developed. Similar to our investigations in ITK-deficient cell lines, both of these new reports demonstrate decreased Ca²⁺ mobilization and other downstream signaling in LAT-deficient Jurkat cell lines (J.CaM2.5, ANJ3), and although, ITK phosphorylation of ITK, is reported to be dependent on LAT, it was not affected in J.CaM2.5. However, the same group (with the higher number of residual T lymphocytes and autoimmunity) had the opportunity to examine calcium flux in CD45RO patient lymphocytes, which was surprisingly within the range of healthy controls 21. Interestingly, all these patients had infectious (often CMV-related) and autoimmune problems, rather than emerging lymphoproliferation. RASGRP1 is a guanine nucleotide exchange factor, which is downstream of the PLC γ 1-mediated cleavage of phosphatidylinositol 4,5-bisphosphate. Mutations in RASGRP1 have also been associated with CD4 T lymphopenia, EBV-driven B cell lymphoma, and lymphoproliferative disease (22, 23).

***Itk*^{−/−} MURINE PHENOTYPE**

The murine *itk*^{−/−} phenotype has been investigated for more than 25 years now, 15 years before the first patients were reported. Most studies had focused on Th1 skewing especially in infectious models; recent data further suggests that *itk*^{−/−} CTLs harbor defects in expansion, degranulation and thus cytotoxicity. In the next chapter we will briefly summarize the *itk*^{−/−} murine phenotype.

Itk^{−/−} mice show an altered development of thymocytes with elevated numbers of innate single positive CD8⁺ (CD8SP) cells. These thymocytes parallel antigen-experienced T cells with a CD122⁺ CD44hiCXCR3⁺ phenotype and increased production of Eomesodermin and IFN γ , if stimulated. Similarly splenocytes (having decreased CD4 and CD8 expression in total) resemble a more differentiated phenotype (CD44⁺) mirroring peripheral CD8 cells of ITK-deficient patients (24–29). NKT cells have an impaired development, are dysfunctional and have a decreased survival in the periphery (30). Most studies, addressing the Th1 and Th2 paradigm suggest that ITK plays a role in a correct Th2 response (19). Upon TCR stimulation, *itk*^{−/−} T cells have an impaired proliferation, less intracellular calcium release and a reduced production of effector cytokines (31).

Few epidemiological studies have observed asthma predisposition and variants in the *ITK* gene (32, 33). Several papers investigated the T lymphocytes dependent airway hyporesponsiveness in *itk*^{−/−} mice. Pathophysiology of asthma usually involves pulmonary infiltration of Th2 cells. Due to an impaired Th2 response *itk*^{−/−} mice show a reduced airway inflammation upon challenge with allergens (32, 34, 35). One group tried to administer an ITK inhibitor as a pharmacologic agent to suppress inflammation in already ovalbumin-induced hyperresponsive airways. Paradoxically, inhibition of ITK induced lymphoid hyperplasia, an observation they attributed to impaired cell death in the absence of cell death (32). Two studies have further focused on the impaired cell death in *itk*^{−/−} mice, which might be at least one explanation for the lymphoproliferation seen in the patients. One study found reduced activation-induced cell death, evidenced by defective FasL upregulation upon activation and elevated T cell proliferation (36).

In recent years, Th17, Treg, and Th9 differentiation have been extensively addressed as well (37–39).

Infections show the impact of ITK on T cell differentiation and T cell effector function. In one of the first studies *itk*^{−/−} mice on a BALB/c background failed to generate the usual Th2 response upon infection with *Leishmania major*, but rather mounted a Th1 dependent IFN γ response, which cleared the infection (31). In further studies *itk*^{−/−} mice showed decreased granuloma formation after challenge with *Schistosoma mansoni* eggs or the nematode *Nippostrongylus brasiliensis*. Both helminths usually induce a Th2 response (31, 40). Upon *S. mansoni* infection compared to WT the size of granuloma and draining lymph nodes was significantly decreased and production of the Th2 cytokines IL-4, IL-5 and IL-10 was markedly reduced in *itk*^{−/−} mice. Again, IFN γ levels were significantly higher suggesting Th1 skewing. If infected with *N. brasiliensis*, wild type BALB/c mice were able to fight the intestinal infection, while *itk*^{−/−} mice showed a decrease in IL-4 and were incapable to clear the worm.

Toxoplasma gondii, on the other hand, promotes Th1 mediated-immunity. Although *itk*^{−/−} mice do succumb to this infection, they are only slightly more susceptible to *T. gondii* than wild type mice (41). Serum IFN- γ levels 5 days after infection and splenic IFN- γ production upon stimulation after 30 days show similar values as wild type mice. Only few studies have addressed the CD8 T cell response in *itk*^{−/−} mice. It was reported that, although *itk*^{−/−} mice do mount protective responses to lymphocytic

choriomeningitis virus Armstrong, vaccinia virus, and vesicular stomatitis virus, viral clearance is delayed, most likely due to poor activation of CD8 T lymphocytes (42, 43). Given the clinical phenotype of the reported patients, a potential role for ITK in CTL function seems highly likely. Recently, the effect of ITK on cytotoxicity and degranulation of CTLs was demonstrated. ITK-deficient CTLs showed decreased expansion and a more naïve phenotype after activation. The authors revealed that in murine *itk*^{-/-} deficient lymphocytes, early stages of cytotoxicity were intact, while defects in degranulation were the bigger concern (44).

As far as we know there has not been any study in which an infection model of the murine gammaherpesvirus 68 (MHV-68) has been investigated in *itk*^{-/-} mice, although murine MHV-68 infection resembles human EBV infection quite a bit. MHV-68 spreads naturally by the respiratory route and is genetically related to EBV (45). Both EBV and MHV-68 have the ability to cause infectious mononucleosis. Following intranasal inoculation the virus causes an acute infection in the lungs and remains in a latent form within B cells. Depending on CD8 T cell function, MHV-68 can further infect other splenic B cells and circulate in other organs. MHV-68 infection has already been investigated in SAP deficient mice (*Sh2d1a*^{-/-}) leading to hypogammaglobulinemia and organ damage (46, 47). Clinically, patients with SAP deficiency have shared features with patients with ITK deficiency, hence we decided to explore the natural course of MHV-68 infection in *itk*^{-/-} mice in some preliminary experiments. B6 and *itk*^{-/-} mice were intranasally infected with MHV-68. There was no difference in the lytic viral titer in lungs between B6 and *itk*^{-/-} infected mice; furthermore, there was no difference in the splenic genomic viral load between B6 and *itk*^{-/-} mice at day 17. Clinically the mice did not behave differently. Similarly to *Sh2d1a*^{-/-} mice after 3 months in total *itk*^{-/-} mice spleens were enlarged, and we could

verify a Vbeta4 expansion in all infected mice, similar to other mouse models after MHV-68 infection. Interestingly, we saw a relative decrease in CD4 cells in *itk*^{-/-} mice; on the other hand, CD8 numbers were similar in both groups. Most importantly we saw a bigger expansion of Vbeta4 cells within in the *itk*^{-/-} group (own preliminary results). The expansion of this clone is line with reports in *Sh2d1a*^{-/-} deficient mice, and further experiments are ongoing to evaluate a potential use of this model to investigate ITK deficiency.

SUMMARY

Since our last review the reported patient number with ITK deficiency has nearly doubled. All patients with previous EBV infection, developed EBV-associated malignancies, like Hodgkin and non-HL and lymphoproliferative diseases, while pulmonary involvement is one of the extranodal key features. Although the number of patients is limited, a curative treatment should be considered. In settings in which an HLA-matched donor is lacking, a haploidentical donor in conjunction with advanced T-depleting and adoptive T cell transfer strategies have improved the outcome. Immunotherapy with anti-CD20 or anti-CD30 can bridge to definitive cure. EBV-negative patients (without any viremia) have not been reported yet, so we are unaware of any problems in these individuals. However, an early transplant might improve outcome. Prospective data collection on HSCT in ITK deficiency and other EBV prone primary immunodeficiencies, as CD27 or CD70 deficiency is highly warranted.

AUTHOR CONTRIBUTIONS

All the authors wrote the manuscript and gathered data.

REFERENCES

- Parvaneh N, Filipovich AH, Borkhardt A. Primary immunodeficiencies predisposed to Epstein-Barr virus-driven haematological diseases. *Br J Haematol* (2013) 162:573–86. doi:10.1111/bjh.12422
- Tangye SG, Palendira U, Edwards ES. Human immunity against EBV-lessons from the clinic. *J Exp Med* (2017) 214:269–83. doi:10.1084/jem.20161846
- Huck K, Feyen O, Niehues T, Ruschendorf F, Hubner N, Laws HJ, et al. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. *J Clin Invest* (2009) 119:1350–8. doi:10.1172/JCI37901
- Ghosh S, Bienemann K, Boztug K, Borkhardt A. Interleukin-2-inducible T-cell kinase (ITK) deficiency – clinical and molecular aspects. *J Clin Immunol* (2014) 34:892–9. doi:10.1007/s10875-014-0110-8
- Alme C, Satwani P, Alobeid B, Bhagat G, Kelly KM. Atypical clinical course in pediatric Hodgkin lymphoma: association with germline mutations in interleukin-2-inducible T-cell kinase. *J Pediatr Hematol Oncol* (2015) 37: 507–8. doi:10.1097/MPH.0000000000000366
- Bienemann K, Borkhardt A, Klapper W, Oeschles I. High incidence of Epstein-Barr virus (EBV)-positive Hodgkin lymphoma and Hodgkin lymphoma-like B-cell lymphoproliferations with EBV latency profile 2 in children with interleukin-2-inducible T-cell kinase deficiency. *Histopathology* (2015) 67:607–16. doi:10.1111/his.12677
- Cagdas D, Erman B, Hanoglu D, Tavil B, Kuskonmaz B, Aydin B, et al. Course of IL-2-inducible T-cell kinase deficiency in a family: lymphomatoid granulomatosis, lymphoma and allogeneic bone marrow transplantation in one sibling; and death in the other. *Bone Marrow Transplant* (2017) 52:126–9. doi:10.1038/bmt.2016.185
- Cipe FE, Aydogmus C, Serwas NK, Tugcu D, Demirkaya M, Bicici FA, et al. ITK deficiency: how can EBV be treated before lymphoma? *Pediatr Blood Cancer* (2015) 62:2247–8. doi:10.1002/pbc.25648
- Linka RM, Risse SL, Bienemann K, Werner M, Linka Y, Krux F, et al. Loss-of-function mutations within the IL-2 inducible kinase ITK in patients with EBV-associated lymphoproliferative diseases. *Leukemia* (2012) 26:963–71. doi:10.1038/leu.2011.371
- Mansouri D, Mahdavi SA, Khalilzadeh S, Mohajerani SA, Hasanazad M, Sadr S, et al. IL-2-inducible T-cell kinase deficiency with pulmonary manifestations due to disseminated Epstein-Barr virus infection. *Int Arch Allergy Immunol* (2012) 158:418–22. doi:10.1159/000333472
- Serwas NK, Cagdas D, Ban SA, Bienemann K, Salzer E, Tezcan I, et al. Identification of ITK deficiency as a novel genetic cause of idiopathic CD4+ T-cell lymphopenia. *Blood* (2014) 124:655–7. doi:10.1182/blood-2014-03-564930
- Stepensky P, Weintraub M, Yanir A, Revel-Vilk S, Krux F, Huck K, et al. IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach. *Haematologica* (2011) 96:472–6. doi:10.3324/haematol.2010.033910
- Booth C, Gilmour KC, Veys P, Gennery AR, Slatter MA, Chapel H, et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. *Blood* (2011) 117:53–62. doi:10.1182/blood-2010-06-284935
- Chung BK, Tsai K, Allan LL, Zheng DJ, Nie JC, Biggs CM, et al. Innate immune control of EBV-infected B cells by invariant natural killer T cells. *Blood* (2013) 122:2600–8. doi:10.1182/blood-2013-01-480665

15. Marsh RA, Madden L, Kitchen BJ, Mody R, McClimon B, Jordan MB, et al. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. *Blood* (2010) 116:1079–82. doi:10.1182/blood-2010-01-256099
16. Okada S, Markle JG, Deenick EK, Mele F, Averbuch D, Lagos M, et al. IMMUNODEFICIENCIES. Impairment of immunity to *Candida* and *Mycobacterium* in humans with bi-allelic RORC mutations. *Science* (2015) 349:606–13. doi:10.1126/science.aaa4282
17. Horwood NJ, Urbaniak AM, Danks L. Tec family kinases in inflammation and disease. *Int Rev Immunol* (2012) 31:87–103. doi:10.3109/08830185.2012.670334
18. Hussain A, Yu L, Faryal R, Mohammad DK, Mohamed AJ, Smith CI. TEC family kinases in health and disease – loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK. *FEBS J* (2011) 278:2001–10. doi:10.1111/j.1742-4658.2011.08134.x
19. Kosaka Y, Felices M, Berg LJ. Itk and Th2 responses: action but no reaction. *Trends Immunol* (2006) 27:453–60. doi:10.1016/j.it.2006.08.006
20. Bacchelli C, Moretti FA, Carmo M, Adams S, Stanescu HC, Pearce K, et al. Mutations in linker for activation of T cells (LAT) lead to a novel form of severe combined immunodeficiency. *J Allergy Clin Immunol* (2017) 139(634–42): e5. doi:10.1016/j.jaci.2016.05.036
21. Keller B, Zaidman I, Yousefi OS, Hershkovitz D, Stein J, Unger S, et al. Early onset combined immunodeficiency and autoimmunity in patients with loss-of-function mutation in LAT. *J Exp Med* (2016) 213:1185–99. doi:10.1084/jem.20151110
22. Platt CD, Fried AJ, Hoyos-Bachiloglu R, Usmani GN, Schmidt B, Whangbo J, et al. Combined immunodeficiency with EBV positive B cell lymphoma and epidermodysplasia verruciformis due to a novel homozygous mutation in RASGRP1. *Clin Immunol* (2017) 183:142–4. doi:10.1016/j.clim.2017.08.007
23. Salzer E, Cagdas D, Hons M, Mace EM, Garnarcz W, Petronczki OY, et al. RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics. *Nat Immunol* (2016) 17:1352–60. doi:10.1038/ni.3575
24. Atherly LO, Lucas JA, Felices M, Yin CC, Reiner SL, Berg LJ. The Tec family tyrosine kinases Itk and Rlk regulate the development of conventional CD8+ T cells. *Immunity* (2006) 25:79–91. doi:10.1016/j.immuni.2006.05.012
25. Blomberg KE, Boucheron N, Lindvall JM, Yu L, Raberger J, Berglof A, et al. Transcriptional signatures of Itk-deficient CD3+, CD4+ and CD8+ T-cells. *BMC Genomics* (2009) 10:233. doi:10.1186/1471-2164-10-233
26. Broussard C, Fleischacker C, Horai R, Chetana M, Venegas AM, Sharp LL, et al. Altered development of CD8+ T cell lineages in mice deficient for the Tec kinases Itk and Rlk. *Immunity* (2006) 25:93–104. doi:10.1016/j.immuni.2006.05.011
27. Dubois S, Waldmann TA, Muller JR. ITK and IL-15 support two distinct subsets of CD8+ T cells. *Proc Natl Acad Sci U S A* (2006) 103:12075–80. doi:10.1073/pnas.0605212103
28. Nayar R, Enos M, Prince A, Shin H, Hemmers S, Jiang JK, et al. TCR signaling via Tec kinase ITK and interferon regulatory factor 4 (IRF4) regulates CD8+ T-cell differentiation. *Proc Natl Acad Sci U S A* (2012) 109:E2794–802. doi:10.1073/pnas.1205742109
29. Readinger JA, Mueller KL, Venegas AM, Horai R, Schwartzberg PL. Tec kinases regulate T-lymphocyte development and function: new insights into the roles of Itk and Rlk/Txk. *Immunol Rev* (2009) 228:93–114. doi:10.1111/j.1600-065X.2008.00757.x
30. Felices M, Berg LJ. The Tec kinases Itk and Rlk regulate NKT cell maturation, cytokine production, and survival. *J Immunol* (2008) 180:3007–18. doi:10.4049/jimmunol.180.5.3007
31. Fowell DJ, Shinkai K, Liao XC, Beebe AM, Coffman RL, Littman DR, et al. Impaired NFATc translocation and failure of Th2 development in Itk-deficient CD4+ T cells. *Immunity* (1999) 11:399–409. doi:10.1016/S1074-7613(00)80115-6
32. Sun Y, Peng I, Webster JD, Suto E, Lesch J, Wu X, et al. Inhibition of the kinase ITK in a mouse model of asthma reduces cell death and fails to inhibit the inflammatory response. *Sci Signal* (2015) 8:ra122. doi:10.1126/scisignal.aab0949
33. Graves PE, Siroux V, Guerra S, Klimecki WT, Martinez FD. Association of atopy and eczema with polymorphisms in T-cell immunoglobulin domain and mucin domain-IL-2-inducible T-cell kinase gene cluster in chromosome 5 q 33. *J Allergy Clin Immunol* (2005) 116:650–6. doi:10.1016/j.jaci.2005.05.004
34. Kannan AK, Sahu N, Mohanan S, Mohinta S, August A. IL-2-inducible T-cell kinase modulates TH2-mediated allergic airway inflammation by suppressing IFN-gamma in naive CD4+ T cells. *J Allergy Clin Immunol* (2013) 132:811–20. e1–5. doi:10.1016/j.jaci.2013.04.033
35. Mueller C, August A. Attenuation of immunological symptoms of allergic asthma in mice lacking the tyrosine kinase ITK. *J Immunol* (2003) 170:5056–63. doi:10.4049/jimmunol.170.10.5056
36. Miller AT, Berg LJ. Defective Fas ligand expression and activation-induced cell death in the absence of IL-2-inducible T cell kinase. *J Immunol* (2002) 168:2163–72. doi:10.4049/jimmunol.168.5.2163
37. Gomez-Rodriguez J, Meylan F, Handon R, Hayes ET, Anderson SM, Kirby MR, et al. Itk is required for Th9 differentiation via TCR-mediated induction of IL-2 and IRF4. *Nat Commun* (2016) 7:10857. doi:10.1038/ncomms10857
38. Gomez-Rodriguez J, Sahu N, Handon R, Davidson TS, Anderson SM, Kirby MR, et al. Differential expression of interleukin-17A and -17F is coupled to T cell receptor signaling via inducible T cell kinase. *Immunity* (2009) 31:587–97. doi:10.1016/j.immuni.2009.07.009
39. Gomez-Rodriguez J, Wohlfert EA, Handon R, Meylan F, Wu JZ, Anderson SM, et al. Itk-mediated integration of T cell receptor and cytokine signaling regulates the balance between Th17 and regulatory T cells. *J Exp Med* (2014) 211:529–43. doi:10.1084/jem.20131459
40. Schaeffer EM, Yap GS, Lewis CM, Czar MJ, McVicar DW, Cheever AW, et al. Mutation of Tec family kinases alters T helper cell differentiation. *Nat Immunol* (2001) 2:1183–8. doi:10.1038/ni734
41. Schaeffer EM, Debnath J, Yap G, McVicar D, Liao XC, Littman DR, et al. Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity. *Science* (1999) 284:638–41. doi:10.1126/science.284.5414.638
42. Atherly LO, Brehm MA, Welsh RM, Berg LJ. Tec kinases Itk and Rlk are required for CD8+ T cell responses to virus infection independent of their role in CD4+ T cell help. *J Immunol* (2006) 176:1571–81. doi:10.4049/jimmunol.176.6.3842
43. Bachmann MF, Littman DR, Liao XC. Antiviral immune responses in Itk-deficient mice. *J Virol* (1997) 71:7253–7.
44. Kapnick SM, Stinchcombe JC, Griffiths GM, Schwartzberg PL. Inducible T cell kinase regulates the acquisition of cytolytic capacity and degranulation in CD8+ CTLs. *J Immunol* (2017) 198:2699–711. doi:10.4049/jimmunol.1601202
45. Sunil-Chandra NP, Arno J, Fazakerley J, Nash AA. Lymphoproliferative disease in mice infected with murine gammaherpesvirus 68. *Am J Pathol* (1994) 145:818–26.
46. Chen G, Tai AK, Lin M, Chang F, Terhorst C, Huber BT. Signaling lymphocyte activation molecule-associated protein is a negative regulator of the CD8 T cell response in mice. *J Immunol* (2005) 175:2212–8. doi:10.4049/jimmunol.175.4.2212
47. Yin L, Al-Alem U, Liang J, Tong WM, Li C, Badiali M, et al. Mice deficient in the X-linked lymphoproliferative disease gene sap exhibit increased susceptibility to murine gammaherpesvirus-68 and hypo-gammaglobulinemia. *J Med Virol* (2003) 71:446–55. doi:10.1002/jmv.10504

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Ghosh, Drexler, Bhatia, Adler, Gennery and Borkhardt. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.